BioInsights - Gene delivery platform evolution - spotlight

CELL & GENE THERAPY INSIGHTS

July 2021

Gene delivery platform evolution

Download PDF

Editorial

Expanding gene therapy and gene editing strategies to large and complex indications

Expanding gene therapy and gene editing strategies to large and complex indications

Carmen Unzu, Florie Borel

Innovator Insight

Scalable upstream process development for the suspension-based production of lentiviral vectors for CAR T cell therapies with multiparallel & benchtop bioreactor systems & DoE methodology

Scalable upstream process development for the suspension-based production of lentiviral vectors for CAR T cell therapies with multiparallel & benchtop bioreactor systems & DoE methodology

D Riethmüller, D Nyamay’antu, D Bollmann

Interview

Next steps in AAV preclinical and translational R&D

Next steps in AAV preclinical and translational R&D

Anna Tretiakova PhD, Shari Gordon

Coming of age: taking the next steps with non-viral gene delivery

Coming of age: taking the next steps with non-viral gene delivery

Matt Stanton

Progressing genetic medicines at the interface of gene therapy and gene editing

Progressing genetic medicines at the interface of gene therapy and gene editing

Dr Albert Seymour

FastFacts

Cell and gene manufacturing: a case study approach to overcoming challenges – expert perspectives and solutions

Cell and gene manufacturing: a case study approach to overcoming challenges – expert perspectives and solutions

Steven Thompson

Plasmid processing for mRNA, gene therapy and other vector applications

Plasmid processing for mRNA, gene therapy and other vector applications

Henrik Ihre

Viewpoint

The dose makes the poison: next generation AAV vectors can save the day

The dose makes the poison: next generation AAV vectors can save the day

Julia Fakhiri, Jihad El Andari

A bright future for lipid nanoparticles in gene therapy

A bright future for lipid nanoparticles in gene therapy

Hongwei Zhang

Next-generation viral vector platforms for gene therapy, vaccine, and oncolytic virotherapy applications

Next-generation viral vector platforms for gene therapy, vaccine, and oncolytic virotherapy applications

Inanç Ortaç